Results 171 to 180 of about 16,832 (328)
ABSTRACT Introduction Medicine is evolving rapidly, requiring continuous education for dentists, particularly in periodontology. Particularly due to the high prevalence of periodontal diseases, treatment needs remain high. While several continuing education programmes are available, outcome assessments are rarely reported.
S. A. Peikert +4 more
wiley +1 more source
Modafinil and its metabolites enhance the anticonvulsant action of classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model [PDF]
Dorota Żółkowska +4 more
openalex +1 more source
Atropine reduces aldicarb-induced sensitivity to C. elegans electroshock model
Nirthieca Suthakaran +5 more
openalex +2 more sources
Log-probit accompanied with Tallarida and Chou-Talalay-Martin methods in an isobolographic analysis of interactions between two antiseizure medications - a comparative study. [PDF]
Łuszczki JJ +2 more
europepmc +1 more source
Abstract Objective Neuropeptides have garnered great interest as potential treatments for epilepsy due to their impact on neuronal excitability through modulation of ion channels and neurotransmitter receptor activity. Neuropeptide Y (NPY) is a 36‐amino acid neuropeptide that is expressed primarily by γ‐aminobutyric acidergic (GABAergic) interneurons ...
Samantha L. Reed +8 more
wiley +1 more source
Ferulic Acid Attenuates Seizure Severity and Enhances Valproate and Carbamazepine Seizure Preventing Efficacy by Regulating Hippocampal Interleukin-1β Level and Antioxidant Capacity in Mice. [PDF]
Taheri E, Hassanpourezatti M.
europepmc +1 more source
In recent years, antiepileptic drug development has been one of the most prominent research areas. Although several new anticonvulsants are already in clinical use, some types of seizures are still not adequately treated with current therapy and have ...
Mutlu Dilsiz Aytemir, Ünsal Çalış
core
Abstract Objective Despite decades of development in anti‐seizure medications, ~30% of individuals remain refractory to all treatments, and none of the existing therapies are disease modifying. Identifying targets outside the current preclinical paradigm is critically important.
Giovanna L. Durante +4 more
wiley +1 more source
From Struggling (With) Screening Tests to Mouse Models of Depression‐Relevant Neurobehavioral States [PDF]
Abstract A major, serendipitous psychiatric discovery is monoamine‐transporter reuptake inhibition as an antidepressant mechanism of action. Chronic treatment with such antidepressants is efficacious, with onset requiring 1‐2 weeks, in many but by no means all patients with major depressive or another stress‐related neuropsychiatric disorder.
Pryce C.
europepmc +2 more sources

